SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is dominating conversations following reports of record-breaking vehicle deliveries for December and the fourth quarter, fueling strong community speculation about the company achieving its first profitable quarter. The electric vehicle maker's performance, alongside extended government subsidies for new energy vehicles in China, is generating bullish sentiment regarding its growth trajectory and competitive position against rivals. Despite some investor concern about market volatility, many remain focused on NIO's operational advancements.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is experiencing high trading volume driven by news of a strategic manufacturing partnership to scale production of its fingerprinting drug screening reader. This announcement has ignited a fierce debate within the trading community, with many anticipating a short squeeze due to the stock's low float, while others express caution regarding potential dilution and pump-and-dump dynamics.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending due to the definitive sale of its Bressner Technology subsidiary for $22.4 million, a strategic move by management to focus on its higher-growth Edge AI compute business and strengthen its balance sheet. The community is actively discussing this, alongside strong anticipation for an imminent multi-hundred-million dollar US Army situational awareness contract, seeing OSS as significantly undervalued within the defense and AI sectors.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is actively trending after a competitor's Cushing's syndrome treatment received a regulatory decline, clearing a significant market hurdle for Xeris's approved drug, Recorlev. The community is buzzing about this as a massive tailwind, expecting substantial market share gains that bolster XERS's already strong financial performance and promising pipeline. Analysts are reflecting this positive outlook, highlighting the company's compelling growth trajectory.

ASP Isotopes, Inc. is a pre-commercial stage advanced materials company, which engages in the development of technology and processes that will allow for the enrichment of natural isotopes into higher concentration products. Its products include medical, green energy, and Industrial isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Washington, DC.

ASP Isotopes Inc

ASP Isotopes is currently trending following key regulatory approvals for its Renergen acquisition and new "Overweight" analyst coverage with a bullish price target. Despite these positive developments, community discussion reflects significant frustration over perceived management missteps, repeated commercial shipment delays, and ongoing dilution concerns. This creates a polarized sentiment, balancing long-term potential in critical isotope markets against short-term execution challenges.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is generating significant buzz due to its sustained upward momentum, driven by a strong rebound in M&A activity and strategic expansions into areas like ETFs. While many in the community are bullish on the firm's performance, others express caution that the stock may be overbought and due for a correction after its rapid ascent.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending due to widespread community discussion surrounding a prominent influencer's bold, yet unfulfilled, prediction of a significant price surge by year-end. While many are mocking the failed forecast, others remain optimistic for 2026, citing potential catalysts like the anticipated Clarity Act, institutional ETF inflows, and upcoming token unlocks as key drivers for its future trajectory.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is trending following mixed interim Phase 2 results for its ARCT-032 cystic fibrosis therapy, which showed signs of mucus plug reduction but limited lung function improvement, leading to significant stock volatility. Community sentiment is divided, with many viewing the sharp decline as an overreaction and highlighting the therapy's biological activity, the strength of their mRNA platform, other pipeline assets, and a high-stakes trade secret lawsuit against AbbVie as key discussion points for future value. Simultaneously, discussions around their influenza vaccine candidates are gaining traction amidst concerns over emerging flu variants.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is trending as its community grapples with the impact of a recent dividend distribution, leading to widespread confusion and frustration over its sharp decline. Many investors are questioning why the 2x leveraged ETF is not tracking its underlying asset, SMCI, as expected, fueling concerns about decay and the potential for a reverse split. While some traders see the current suppressed levels as a buying opportunity, others warn of the significant volatility and risks inherent in such leveraged products.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after its relacorilant drug for Cushing's syndrome received a Complete Response Letter from the FDA, requesting additional efficacy evidence despite a successful pivotal trial, causing a sharp stock decline. Many investors view this over 50% drop as an overreaction, highlighting the company's established, revenue-generating drug Korlym and its broader pipeline. Amidst year-end tax-loss selling and wider biotech sector volatility, community discussion centers on the potential for regulatory resolution versus further valuation adjustments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Can These 3 ETF Losers of 2025 Rebound in 2026?

Can beaten-down cloud ETFs like WCLD, staples ETF FXG, and India ETFs INCO & INQQ stage a rebound in 2026 after a mixed 2025?

 6 ETF Predictions for 2026

2026 could favor SPY, SLV, KBWB, TAN & global ETFs as AI, metals, banks and clean energy shape the next leg of market gains.

Is WisdomTree Cloud Computing ETF (WCLD) a Strong ETF Right Now?

Should You Invest in the First Trust Cloud Computing ETF (SKYY)?

Is First Trust Cloud Computing ETF (SKYY) a Strong ETF Right Now?

Should You Invest in the Global X Cloud Computing ETF (CLOU)?

Should You Invest in the WisdomTree Cloud Computing ETF (WCLD)?

Shares of cloud-based software platform Monday.com soared nearly 11% after the company reported its first quarter of operating profitability. The firm reported a 34% year-over-year (YoY) rise in its second-quarter revenue at $236.10 million, surpassing an analyst estimate of $229.09 million.Diluted earnings per share (EPS) came in at $0.94 versus an estimate of $0.56. Net income stood at $14.32 million compared to a net loss of $7.04 million in the same quarter a year ago.The firm also raised its full-year guidance and now expects total revenue of $956 million to $961 million, representing year-over-year growth of 31% to 32% versus a prior guidance of $942 million to $948 million.Non-GAAP operating income is expected in the range of $100 million to $105 million with an operating margin of 10% to 11% — higher than an earlier guidance of $77 million to $83 million and operating margin of 8% to 9%.Following the announcement, retail sentiment flipped into the ‘extremely bullish’ territory (76/100) from the ‘neutral zone’ a day ago. The move was accompanied by ‘extremely high’ message volumes (91/100).<figure class="image"><a href="https://stocktwits.com/symbol/MNDY"><img style="aspect-ratio:1892/530;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_12_at_2_45_11_PM_d1d2ad961a.png" alt="Monday.com sentiment meter as of 2:16 p.m. EST on August 12, 2024" width="1892" height="530"></a><figcaption>Monday.com sentiment meter as of 2:16 p.m. EST on August 12, 2024</figcaption></figure>Monday.com also witnessed a significant growth in some of its critical metrics. For instance, the number of paid customers with more than $100,000 in ARR stood at 1,009, rising 49% from the same period last year. Similarly, the number of paid customers with more than $50,000 in ARR rose 43% YoY to 2,713.The firm’s co-founders and co-CEOs, Roy Mann and Eran Zinman noted that the company continues to drive strong and efficient growth, while constantly innovating to ensure that its go-to-market strategy, products, and platform can effectively scale as customers grow. “In Q2, these ongoing investments enabled us to more than triple our largest seat count as we continue to focus on expanding upmarket,” they said.Stocktwits users are expressing optimism that shares of the firm may nudge the $260-mark given the positive report.<stembedurl>https://stocktwits.com/LoadRunner/message/582616157</stembedurl>

The company reported its first quarter of operating profitability and a 34% year-over-year rise in its second-quarter revenue.

No Monday Blues For Monday.com – Retail Cheers Solid Q2

Shares of cloud-based software platform Monday.com soared nearly 11% after the company reported its first quarter of operating profitability.

Monday.com Stock rises after q2 earnings

Equity

The project management software company reported its first quarter of operating profitability and a 34% year-over-year rise in its second-quarter revenue. Following the announcement, retail sentiment flipped into the ‘extremely bullish’ territory on Stocktwits.

Current Price	$35.01
Prev Close	$35.38
Open	$35.35
Dividend Yield	N/A
50-Day Moving Average	$35.02
Beta	N/A
Avg. Volume	391,872.16
PE Ratio	N/A

52-Week High	$41.68
52-Week Low	$27.14
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

WCLD
WisdomTree Cloud Computing Fund

Feed

News

Sentiment

Fundamentals

Info

Latest WCLD News

WCLDWisdomTree Cloud Computing Fund